Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis.
作者信息
Mantero Vittorio, Baroncini Damiano, Balgera Roberto, Guaschino Clara, Basilico Paola, Annovazzi Pietro, Zaffaroni Mauro, Salmaggi Andrea, Cordano Christian
机构信息
Department of Neurology, MS Center, ASST Lecco, Via dell'Eremo 9/11, 23900, Lecco, Italy.
MS Center, Gallarate Hospital, ASST Valle Olona, Gallarate, Italy.
出版信息
J Neurol. 2021 Jun;268(6):2029-2030. doi: 10.1007/s00415-020-10196-9. Epub 2020 Aug 31.
Abstract
摘要
相似文献
1
Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis.一群接受特立氟胺治疗的多发性硬化症患者中的轻度新冠病毒感染。
J Neurol. 2021 Jun;268(6):2029-2030. doi: 10.1007/s00415-020-10196-9. Epub 2020 Aug 31.
2
COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.阿根廷接受特立氟胺治疗的多发性硬化症患者中的 COVID-19：首个全国病例系列。
Mult Scler Relat Disord. 2021 Aug;53:103049. doi: 10.1016/j.msard.2021.103049. Epub 2021 May 30.
3
Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.特立氟胺用于治疗复发缓解型多发性硬化症。
Expert Rev Clin Immunol. 2015 Feb;11(2):181-94. doi: 10.1586/1744666X.2015.993611. Epub 2014 Dec 16.
4
Rebound syndrome in two cases of MS patients after teriflunomide cessation.两名多发性硬化症患者停用特立氟胺后的反跳综合征。
Acta Neurol Belg. 2022 Oct;122(5):1381-1384. doi: 10.1007/s13760-022-01929-w. Epub 2022 Jul 8.
5
Chronic necrotizing aspergillosis: A new risk with teriflunomide in multiple sclerosis patients?慢性坏死性曲霉病：多发性硬化症患者使用来氟米特会带来新风险？
Rev Neurol (Paris). 2022 Mar;178(3):266-267. doi: 10.1016/j.neurol.2021.06.012. Epub 2021 Sep 24.
6
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.一名复发型多发性硬化症患者在接受特立氟胺治疗时发生致命性中毒性表皮坏死松解症。
Mult Scler. 2015 Oct;21(11):1476-7. doi: 10.1177/1352458515596601. Epub 2015 Jul 21.
7
COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review.COVID-19 在多发性硬化症接受特立氟胺治疗的患者中的病例报告和文献复习。
Mult Scler Relat Disord. 2021 Feb;48:102734. doi: 10.1016/j.msard.2020.102734. Epub 2021 Jan 2.
8
Palmar pustular psoriasis associated with teriflunomide treatment.手掌脓疱性银屑病与特立氟胺治疗相关。
Mult Scler Relat Disord. 2019 Jan;27:400-402. doi: 10.1016/j.msard.2018.11.020. Epub 2018 Nov 19.
9
A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis.一名正在接受特立氟胺治疗复发型多发性硬化症的患者发生淋巴瘤的病例。
Mult Scler Relat Disord. 2017 Oct;17:92-94. doi: 10.1016/j.msard.2017.07.001. Epub 2017 Jul 3.
10
Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.与多发性硬化症患者的特立氟胺相关的严重高甘油三酯血症：一例报告。
Mult Scler. 2018 Sep;24(10):1383-1385. doi: 10.1177/1352458518761185. Epub 2018 Feb 23.
引用本文的文献
1
Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic Changes.来氟米特可使新冠肺炎快速康复，并伴有短暂的免疫变化。
J Immunol Sci. 2023;7(1):9-27. doi: 10.29245/2578-3009/2023/1.1241. Epub 2023 Jan 20.
2
SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot.用芬戈莫德治疗的多发性硬化症患者接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗：在优先接种第三针后可能产生保护性体液免疫反应。
Vaccines (Basel). 2022 Feb 21;10(2):341. doi: 10.3390/vaccines10020341.
3
Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination.多发性硬化症患者与疾病修正疗法：对针对2019冠状病毒病和严重急性呼吸综合征冠状病毒2疫苗接种的免疫反应的影响
Vaccines (Basel). 2022 Feb 11;10(2):279. doi: 10.3390/vaccines10020279.
4
Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.特立氟胺治疗多发性硬化症选择性调节 CD8 记忆 T 细胞。
Front Immunol. 2021 Oct 5;12:730342. doi: 10.3389/fimmu.2021.730342. eCollection 2021.
5
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.多发性硬化症、疾病修正疗法与2019冠状病毒病：关于免疫反应和疫苗接种建议的系统综述
Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.
6
The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China.中国全国多发性硬化症患者样本中新冠病毒肺炎的流行病学及与多发性硬化症相关的特征
Front Neurol. 2021 May 28;12:682729. doi: 10.3389/fneur.2021.682729. eCollection 2021.
7
Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.二氢乳清酸脱氢酶（DHODH）抑制剂“来氟米特”和“特立氟胺”在新冠病毒感染中的疗效和安全性：一项叙述性综述。
Eur J Pharmacol. 2021 Sep 5;906:174233. doi: 10.1016/j.ejphar.2021.174233. Epub 2021 Jun 7.
8
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.多发性硬化症的疾病修正治疗和 SARS-CoV-2 疫苗接种：专家共识。
J Neurol. 2021 Nov;268(11):3961-3968. doi: 10.1007/s00415-021-10545-2. Epub 2021 Apr 12.
9
Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint.COVID-19 大流行期间治疗多发性硬化症的药物：批判性观点。
Curr Neuropharmacol. 2022;20(1):107-125. doi: 10.2174/1570159X19666210330094017.
10
Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes.新型冠状病毒病 2019（COVID-19）在风湿性疾病患者中的流行病学和结局。
Best Pract Res Clin Rheumatol. 2021 Mar;35(1):101657. doi: 10.1016/j.berh.2020.101657. Epub 2020 Dec 23.
本文引用的文献
1
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.一例类风湿关节炎合并 COVID-19 患者应用托珠单抗治疗的复杂病例
Clin Rheumatol. 2020 Sep;39(9):2797-2802. doi: 10.1007/s10067-020-05234-w. Epub 2020 Jun 19.
2
Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?利妥昔单抗治疗多发性硬化症患者合并 COVID-19：整合素阻断是否具有保护作用？
Mult Scler Relat Disord. 2020 Sep;44:102250. doi: 10.1016/j.msard.2020.102250. Epub 2020 Jun 3.
3
Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.阿仑单抗治疗新型冠状病毒肺炎大流行期间的多发性硬化症：尽管免疫抑制严重，但感染轻微且无并发症。
Mult Scler. 2020 Sep;26(10):1268-1269. doi: 10.1177/1352458520926459. Epub 2020 May 28.
4
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.B 细胞耗竭疗法可能会影响伊朗 COVID-19 疫情早期多发性硬化症患者急性呼吸道疾病的易感性。
Mult Scler Relat Disord. 2020 Aug;43:102195. doi: 10.1016/j.msard.2020.102195. Epub 2020 May 13.
5
An Italian programme for COVID-19 infection in multiple sclerosis.一项针对多发性硬化症患者新冠病毒感染情况的意大利项目。
Lancet Neurol. 2020 Jun;19(6):481-482. doi: 10.1016/S1474-4422(20)30147-2. Epub 2020 Apr 30.
6
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?奥瑞珠单抗治疗多发性硬化症患者合并 COVID-19：免疫抑制是否具有保护作用？
Mult Scler Relat Disord. 2020 Jul;42:102120. doi: 10.1016/j.msard.2020.102120. Epub 2020 Apr 15.
7
Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.在2019冠状病毒病大流行期间治疗多发性硬化症和视神经脊髓炎谱系障碍。
Neurology. 2020 Jun 2;94(22):949-952. doi: 10.1212/WNL.0000000000009507. Epub 2020 Apr 2.
8
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.多发性硬化症患者接受芬戈莫德、那他珠单抗、利妥昔单抗和注射治疗的感染风险。
JAMA Neurol. 2020 Feb 1;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365.
9
Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation.感染作为多发性硬化症病情加重的环境触发因素。
Front Immunol. 2015 Oct 19;6:520. doi: 10.3389/fimmu.2015.00520. eCollection 2015.
10
Characterization of procollagen type IV and of its heterogenous accumulation products in the extracellular matrix of bovine lens cells in culture.培养的牛晶状体细胞细胞外基质中IV型前胶原及其异质性积聚产物的特性分析
Int J Biochem. 1981;13(1):63-70. doi: 10.1016/0020-711x(81)90137-3.
Zotero 插件